ardx-20211130
0001437402false00014374022021-11-302021-11-300001437402dei:OtherAddressMember2021-11-302021-11-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 30, 2021
https://cdn.kscope.io/f105b38ab3b8a078f1e0c0692628701e-ardx-20211130_g1.jpg
ARDELYX, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3648526-1303944
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)

400 FIFTH AVE.SUITE 210WALTHAMMASSACHUSETTS 02451
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (510745-1700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001ARDXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o



Item 8.01 Other Events.

On November 30, 2021, Ardelyx, Inc. (the “Company”) announced plans to launch IBSRELA, the Company’s approved treatment for irritable bowel syndrome with constipation (“IBS-C”) in adults, in the second quarter 2022.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.
Exhibit
No.
Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 30, 2021ARDELYX, INC.
By:/s/ Justin Renz
Justin Renz
Chief Financial Officer